Moving research from bench to bedside to community: There is still more to do

Journal of Clinical Oncology

Volumn 26, Issue 4, 2008, Pages 523-526

  Kahn, Katherine L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ANOREXIA; ARTHRALGIA; BREAST CANCER; CANCER SCREENING; CLINICAL TRIAL; COMMUNITY; DRUG WITHDRAWAL; EDITORIAL; ENDOMETRIUM CANCER; EVIDENCE BASED MEDICINE; FRACTURE; HORMONAL THERAPY; HOSPITAL; HOT FLUSH; HUMAN; MEDICAL RESEARCH; MONOTHERAPY; MORTALITY; MYALGIA; OSTEOLYSIS; POSTMENOPAUSE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; THROMBOEMBOLISM; UTERUS SARCOMA; VAGINA DISCHARGE; BREAST TUMOR; COMMUNITY CARE; DISEASE FREE SURVIVAL; DRUG COST; ECONOMICS; FEMALE; FORECASTING; NOTE; ORGANIZATION AND MANAGEMENT; RESEARCH; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CALIFORNIA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMMUNITY HEALTH SERVICES; DISEASE-FREE SURVIVAL; DRUG COSTS; EVIDENCE-BASED MEDICINE; FEMALE; FORECASTING; HUMANS; RESEARCH; TAMOXIFEN;

EID: 39149095998     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.1870     Document Type: Editorial

References (63)

1. Mathieu MP: PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2005/2006. Waltham, MA, Barnett Educational Services, 2005
2. Sung NS, Crowley WF, Genel M: Central challenges facing the national clinical research enterprise. JAMA 289:1278-1287, 2003
3. Jemal A, Ward E, Thun MJ: Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9:R28, 2007
4. Surveillance, Epidemiology and End Results (SEER) program: National Cancer Institute DCCPS Surveillance Research Program, Cancer Statistics Branch. http://www.seer.cancer.gov
5. Chu KC, Tarone RE, Kessler LG, et al: Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 88:1571-1579, 1996
6. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005
7. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
8. Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101, 1998
9. Stewart HJ, Prescott RJ, Forrest AP: Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years. J Natl Cancer Inst 93:456-462, 2001
10. Delozier T, Spielmann M, Mace-Lesec'h J, et al: Tamoxifen adjuvant treatment duration in early breast cancer: Initial results of a randomized study comparing short-term treatment with long-term treatment - Federation Nationale des Centres de Lutte Contre le Cancer Breast Group. J Clin Oncol 18:3507-3512, 2000
11. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer: Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst 88:1543-1549, 1996
12. Belfiglio M, Valentini M, Pellegrini F, et al: Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). Cancer 104:2334-2339, 2005
13. Tormey DC, Gray R, Falkson HC: Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer: Eastern Cooperative Oncology Group. J Natl Cancer Inst 88:1828-1833, 1996
14. Bryant J, Fisher B, Dignam J: Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr 56-61, 2001
15. Davies C, Nomura Y, Ohashi Y: [Adjuvant tamoxifen duration: More large-scale randomized evidence is needed]. Gan To Kagaku Ryoho 24:1203-1209, 1997
16. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-1662, 2005
17. Wapnir IL, Anderson SJ, Mamounas EP, et al: Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24:2028-2037, 2006
18. Clinical Trial Service Unit: Adjuvant tamoxifen longer against shorter (ATLAS), Protocol, April 1995: ATLAS Office. Oxford, England, Radcliffe Infirmary, 1995
19. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 23:619-629, 2005
20. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003
21. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
22. Thürlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
23. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
24. Boccardo F, Rubagotti A, Puntoni M, et al: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138-5147, 2005
25. Jakesz R, Jonat W, Gnant M, et al: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462, 2005
26. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
27. Dowsett M, Cuzick J, Wale C, et al: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol 23:7512-7517, 2005
28. Ingle JN, Tu D, Pater JL, et al: Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA 17 extended adjuvant therapy trial. Breast Cancer Res Treat 99:295-300, 2006
29. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618, 1998
30. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537, 1994
31. Chalas E, Costantino JP, Wickerham DL, et al: Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 192:1230-1237, 2005
32. Kedar RP, Bourne TH, Powles TJ, et al: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343:1318-1321, 1994
33. Lahti E, Blanco G, Kauppila A, et al: Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81:660-664, 1993
34. Swerdlow AJ, Jones ME: Tamoxifen treatment for breast cancer and risk of endometrial cancer: A case-control study. J Natl Cancer Inst 97:375-384, 2005
35. Braithwaite RS, Chlebowski RT, Lau J, et al: Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937-947, 2003
36. Lønning PE, Geisler J, Krag LE, et al: Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126-5137, 2005
37. Grunfeld EA, Hunter MS, Sikka P, et al: Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97-102, 2005
38. Kahn KL, Schneider EC, Malin JL, et al: Patient centered experiences in breast cancer: Predicting long-term adherence to tamoxifen use. Med Care 45:431-439, 2007
39. Yoon J, Malin JL, Tao ML, et al: Symptoms after breast cancer treatment: Are they influenced by patient characteristics? Breast Cancer Res Treat 2007
40. Day R, Ganz PA, Costantino JP, et al: Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17:2659-2669, 1999
41. Owusu C, Buist DS, Field TS, et al: Predictors of tamoxifen discontinuation among older women with estrogen-receptor positive breast cancer. J Clin Oncol doi: 10.1200/JCO.2006.10.1022
42. Partridge AH, LaFountain A, Mayer E, et al: Adherence to initial adjuvant anastozole therapy among women with early stage breast cancer. J Clin Oncol 26:556-562, 2008
43. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 353:487-497, 2005
44. Demissie S, Silliman RA, Lash TL: Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322-328, 2001
45. Lash TL, Fox MP, Westrup JL, et al: Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215-220, 2006
46. Atkins L, Fallowfield L: Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42:2271-2276, 2006
47. Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67-74, 1986
48. Yoon J, Malin JL, Tisnado DM, et al: Symptom management after breast cancer treatment: Is it influenced by patient characteristics? Breast Cancer Res Treat [epub ahead of print on July 19, 2007]
49. Haynes RB, McDonald HP, Garg AX: Helping patients follow prescribed treatment: Clinical applications. JAMA 288:2880-2883, 2002
50. Simoni JM, Frick PA, Pantalone DW, et al: Antiretroviral adherence interventions: A review of current literature and ongoing studies. Top HIV Med 11:185-198, 2003
51. Tuldrá A, Fumaz CR, Ferrer MJ, et al: Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 25:221-228, 2000
52. Feldman R, Bacher M, Campbell N, et al: Adherence to pharmacologic management of hypertension. Can J Public Health 89:I16-I18, 1998
53. Ran MS, Xiang MZ, Chan CL, et al: Effectiveness of psychoeducational intervention for rural Chinese families experiencing schizophrenia: A randomised controlled trial. Soc Psychiatry Psychiatr Epidemiol 38:69-75, 2003
54. Zygmunt A, Olfson M, Boyer CA, et al: Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 159:1653-1664, 2002
55. National Comprehensive Cancer Network (NCCN) Breast Cancer (version IX) Clinical Practice Guidelines in Oncology. http://www.nccn.org
56. Goldhirsch A, Glick J, Gelber R, et al: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1601-1608, 1998
57. DiMatteo MR, Sherbourne CD, Hays RD, et al: Physicians' characteristics influence patients' adherence to medical treatment: Results from the Medical Outcomes Study. Health Psychol 12:93-102, 1993
58. PPA: Partnership for Prescription Assistance Program 2007. http://www.pparx.org/
59. RXHelpForCalifornians: RX Help for Californians 2007. http://www.rxhelpforca.org
60. Haynes R, Yan X, Degani A, et al: Interventions for Enhancing Medication Adherence (Review). Cochrane Database Syst Rev 4:CD000011, 2005
61. Sabate E: Adherence to Long Term Therapies: Evidence for Action. Geneva, Switzerland, World Health Organization, 2003
62. Malin JL, Schneider EC, Epstein AM, et al: Results of the National Initiative for Cancer Care Quality: How can we improve the quality of cancer care in the United States? J Clin Oncol 24:626-634, 2006
63. McGlynn EA, Asch SM, Adams J, et al: The quality of health care delivered to adults in the United States. N Engl J Med 348:2635-2645, 2003